Autogenous vaccine: the best therapy for perianal condyloma acuminata?
OBJECTIVE
Treatment of perianal condyloma acuminata is frustrating because most treatment options are fraught with high recurrence rates and patient discomfort. We propose that surgical excision followed by vaccination with an autogenous condyloma acuminata vaccine is the most effective therapy available in primary and recurrent perianal condyloma acuminata.


METHODS
Eighty-three patients with perianal condyloma acuminata were treated from 1985 to 1992. Treatment was divided for patients as follows: surgical excision, 20; bichloroacetic acid, 10; podophyllin and interferon A, 5; excision followed by autogenous condyloma acuminata vaccination twice weekly using 0.1 ml subcutaneously for three weeks increasing to 1.0 ml subcutaneously for seven weeks, 43. Syphilis was diagnosed in seven patients; two were human immunovirus-positive. All but three patients were male. Of those patients treated with the vaccination protocol, 25 had primary and 18 had recurrent disease.


RESULTS
Recurrence rates were: excision alone and bichloroacetic acid, 50 percent; podophyllin and interferon A, 85 percent; whereas only 4.6 percent recurred when treated with excision and vaccination. Mean follow-up was 13 (range, 6-23) months. All patients treated with the vaccination protocol tolerated the full course of therapy.


CONCLUSIONS
We believe that excision of perianal condyloma acuminata followed by autogenous condyloma acuminata vaccination for approximately ten weeks is the most effective and definitive treatment option and, moreover, should be considered in all patients with perianal condyloma acuminata.
Wiltz
O H
OH
Department of Colon and Rectal Surgery, Hospital San Jorge, San Juan, Puerto Rico.
Torregrosa
M
M
Wiltz
O
O
D000328:Adult; D001004:Anus Diseases / Q000601:surgery / Q000628:therapy* / Q000821:virology*; D003131:Combined Modality Therapy; D003218:Condylomata Acuminata / Q000601:surgery / Q000628:therapy* / Q000821:virology; D003999:Dichloroacetic Acid / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000150:complications; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D027383:Papillomaviridae / Q000276:immunology*; D011033:Podophyllin / Q000627:therapeutic use; D012008:Recurrence; D012189:Retrospective Studies; D013587:Syphilis / Q000150:complications; D014765:Viral Vaccines / Q000008:administration & dosage
D016898:Interferon-alpha; D014765:Viral Vaccines; D011033:Podophyllin; D003999:Dichloroacetic Acid